# 9MW2921

Source: https://onco.cc/drugs/9mw2921/  
OnCo record `9mw2921` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

9MW2921 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.

## Summary

ASCO 2025 abstract 3029 reports 39 treated patients at the November 12, 2024 cutoff. Across doses, 12/38 efficacy-evaluable patients had partial responses. At 3.0 mg/kg, responses were 8/19 (42.1%); this is a dose subgroup, not the full treated population. All three patients at 4.5 mg/kg experienced dose-limiting toxicity and that dose was considered intolerable. The nonrandomized solid-tumor study does not establish TNBC-specific benefit.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: TROP2-directed ADC carrying a camptothecin-based Mtoxin payload with site-specific conjugation.
- Payload: Mtoxin (camptothecin-based payload), DAR 4

## Sources

- Publisher abstract: https://doi.org/10.1200/jco.2025.43.16_suppl.3029
- ClinicalTrials.gov NCT05990452: https://clinicaltrials.gov/study/NCT05990452

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05990452/)

---
JSON: https://onco.cc/api/v1/entities/9mw2921.json